Mabuterol

Mabuterol

SCHEMBL82440

CC(C)(C)NCC(O)c1cc(Cl)c(N)c(C(F)(F)F)c1

nearest known ligand 0.76

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 10/20 0.76
ADRB1 P08588 5/20 0.76
LMNA P02545 3/20 0.76
TSHR P16473 2/20 0.76
HTR1A P08908 1/20 0.76
SLC6A2 P23975 1/20 0.76
SLC6A4 P31645 1/20 0.76
ADRA1A P35348 1/20 0.76
OPRK1 P41145 1/20 0.76
SLC6A3 Q01959 1/20 0.76
CYP3A4 P08684 2/20 0.74
KDM4E B2RXH2 2/20 0.74
CASP7 P55210 2/20 0.50
HIF1A Q16665 2/20 0.50
CYP2C9 P11712 1/20 0.50
KMT2A Q03164 1/20 0.50
CASP1 P29466 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Mabuterol SCHEMBL123796 0.99 LMNA (0.77) ADRB2ADRB1LMNATSHRHTR1A
Mabuterol SCHEMBL29384375 0.99 LMNA (0.77) ADRB2ADRB1LMNATSHRHTR1A
Mabuterol SCHEMBL29576601 0.91 ADRB2 (0.63) ADRB2ADRB1LMNATSHRHTR1A
SCHEMBL11026998 0.88 ADRB2 (0.59) ADRB2ADRB1LMNATSHRHTR1A
SCHEMBL4882139 0.88 ADRB2 (0.59) ADRB2ADRB1LMNATSHRHTR1A
Mabuterol SCHEMBL21623862 0.88 ADRB2 (0.59) ADRB2ADRB1LMNATSHRHTR1A
Hydrochloric Acid SCHEMBL11054918 0.87 LMNA (0.60) ADRB2ADRB1LMNATSHRHTR1A
Clenbuterol SCHEMBL4722 0.87 ADRB1 (1.00) ADRB2ADRB1LMNATSHRHTR1A
Clenbuterol SCHEMBL20761507 0.87 ADRB1 (1.00) ADRB2ADRB1LMNATSHRHTR1A
Clenbuterol SCHEMBL4723 0.87 ADRB1 (1.00) ADRB2ADRB1LMNATSHRHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 3829 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4255391-B1 LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION METRIOPHARM AG (CH) 2026-05-06 EP claimed
US-20250134835-A1 COMPOSITIONS AND METHODS FOR TREATING PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) CURASEN THERAPEUTICS, INC. 2025-05-01 US claimed
US-20250017878-A1 USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY CHRONIC AIRWAY THERAPEUTICS LTD (AU) 2025-01-16 US claimed
US-20240398729-A1 Methods and Compositions for the Treatment of Cytoplasmic Glycogen Storage Disorders DUKE UNIVERSITY (US) 2024-12-05 US claimed
EP-4126138-B1 AEROSOL DELIVERY OF AT LEAST TWO LIQUID COMPOSITIONS INVOX BELGIUM NV (BE) 2024-10-16 EP claimed
US-20240325413-A1 FORMULATIONS FOR THE TREATMENT OF RESPIRATORY DISORDERS 484 SCIENCE CORP (CA) 2024-10-03 US claimed
WO-2024189434-A1 USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2 CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) 2024-09-19 WO claimed
US-20240270855-A1 NEURO-MESENCHYME UNITS CONTROL ILC2 AND OBESITY VIA A BRAIN-ADIPOSE CIRCUIT FUNDAÇÃO D. ANNA DE SOMMER CHAMPALIMAUD E DR. CARLOS MONTEZ CHAMPALIMAUD (PT) 2024-08-15 US claimed
WO-2024137478-A1 METHODS FOR TREATING VARIOUS CONDITIONS AND INDICATIONS WITH AGONISTS AND ANTAGONISTS CURASEN THERAPEUTICS, INC. (US) 2024-06-27 WO claimed
US-20240189244-A1 COMPOSITIONS AND METHODS FOR DELIVERING PHARMACEUTICAL AGENTS ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA 2024-06-13 US claimed
WO-1996019198-A1 AEROSOL DRUG FORMULATIONS ASTRA AKTIEBOLAG (SE) 1996-06-27 WO claimed
US-5312627-A Polymer matrix with drugs with bronchodilator agents ZAMBON GROUP S.P.A. (IT) 1994-05-17 US claimed
EP-0523537-A1 Transdermal therapeutic system for the administration of drugs having bronchodilating activity ZAMBON GROUP S.p.A. (IT) 1993-01-20 EP claimed
EP-0341559-A2 Synergistic mixtures and their therapeutical use BOEHRINGER INGELHEIM KG (DE) 1989-11-15 EP claimed
EP-0338507-A2 Use of mabuterol and related compounds for intraocular pressure adjustment Basotherm GmbH (DE) 1989-10-25 EP claimed
EP-0298984-A1 COMPOSITIONS OF LIPOSOMES AND $g(b) 2?-RECEPTOR ACTIVE SUBSTANCES Aktiebolaget Draco (SE) 1989-01-18 EP claimed
WO-1987005803-A1 COMPOSITIONS OF LIPOSOMES AND beta2-RECEPTOR ACTIVE SUBSTANCES AKTIEBOLAGET DRACO (SE) 1987-10-08 WO claimed
EP-0201732-A2 Beta-2-mimetics of the 4-aminophenylethanolamine type for the prevention of peptic ulcers BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) 1986-11-20 EP claimed
EP-0057900-B1 ANIMAL FEED ADDITIVE FOR IMPROVING GROWTH Dr. Karl Thomae GmbH (DE) 1985-05-08 EP claimed
US-4119710-A ANALGESICS, UTEROSPASMOLYTICS, ANTISPASTICS, BLOCKING AGENTS BOEHRINGER INGELHEIM GMBH (DE) 1978-10-10 US claimed